Johnson & Johnson (NYSE: JNJ) is one of the world's largest and most prominent healthcare leaders. Furthermore, revenue ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

We recently compiled a list of the 10 Most Promising Dividend Stocks According to Hedge Funds. In this article, we are going ...

Johnson & Johnson (NYSE: JNJ) will present at the 45th Annual TD Cowen Healthcare Conference on Tuesday, March 4th, 2025. Management will participate in a fireside chat at 11:10 a.m. Eastern Time.

The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates ...

Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

Guggenheim analyst Vamil Divan raised the firm’s price target on Johnson & Johnson to $166 from $162 and keeps a Neutral rating on the ...

JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price ...

Multinational healthcare company Johnson & Johnson (NYSE:JNJ) in Q4 CY2024, with sales up 5.3% year on year to $22.52 billion ...

Analysts expect a profit per share of $2.02, which is a decline of 11.8% from the prior year period. The consensus revenue ...

We recently compiled a list of the Retirement Stock Portfolio: 10 Healthcare Stocks to Buy. In this article, we are going to ...